Summary & Overview
HCPCS Level II J1747: Injection, spesolimab-sbzo, 1 mg
HCPCS Level II code J1747 designates a 1 mg injection of spesolimab-sbzo, a monoclonal antibody administered as a parenteral biologic therapy. This national-level billing code is used to report individual billed units of the drug across outpatient infusion centers, hospital outpatient departments, and physician offices. Accurate coding of high-cost biologics like spesolimab-sbzo is important for claims processing, benefit determination, and coverage policy application.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how J1747 is used in practice, what sites of service commonly bill the code, and the implications for payer coverage and prior authorization processes.
Readers will find benchmarks and billing context for J1747 (where available), a summary of payer coverage considerations, and clinical context explaining the service type and typical settings. The report also highlights common billing modifiers and notes on administrative handling of injectable biologics. Data not available in the input will be explicitly marked as such where applicable.
Billing Code Overview
HCPCS Level II code J1747 represents an injection of spesolimab-sbzo, 1 mg. This code denotes a billed unit of the specified monoclonal antibody therapy administered by injection. The service type is an injectable biologic/infusion therapy provided as a parenteral medication dose.
The typical site of service for this HCPCS Level II code is outpatient infusion or injection settings, which may include hospital outpatient departments, ambulatory infusion centers, physician offices, and specialty clinics that administer parenteral biologic therapies.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a specialty infusion clinic or outpatient hospital infusion center for administration of J1747 (spesolimab-sbzo, 1 mg) for treatment of a flare or to maintain control of a recognized autoinflammatory condition for which spesolimab is indicated. The patient has a recent diagnosis confirmed by the treating specialist (dermatologist, rheumatologist, or immunologist) and has baseline assessment completed: vital signs, medication allergy review, and documentation of indication and prior therapies. An informed consent discussion and pre-infusion checklist are completed.
The clinical workflow includes medication verification and dose calculation based on the prescribed milligram amount, pharmacy preparation under sterile technique, and transport to the infusion area. A registered nurse or licensed clinician verifies patient identity, confirms indication and orders, and administers the injection or intravenous infusion per product-specific administration instructions. Observation for infusion-related reactions or hypersensitivity occurs during and after administration per institutional protocol. Documentation includes lot number, NDC if required, amount administered in milligrams, route, site (if applicable), and any modifier usage to reflect special circumstances such as modifier JZ for single-use vial compliance or 52 for reduced services. Billing uses J1747 with appropriate modifiers and linked ICD-10 diagnosis codes that reflect the treated condition.
Coding Specifications
| Modifier | Description |
|---|